Overview
MindMed is a clinical-stage psychedelic medicine company developing novel therapeutics derived from LSD, MDMA, and ibogaine analogs for neurological and psychiatric disorders. Their lead asset MM120 (LSD tartrate) has shown promising Phase 2b results for generalized anxiety disorder.
More in Psychedelics
Latest industry news
Tianjin University Unveils a 3-Gram Non-Invasive BCI That Disappears Into Your Hair
2026-10-04 · Research
Neuralink Pretrained on 50,000 Hours of Unlabeled Brain Data — and the Implications Are Enormous
2026-10-03 · Research
BlueWind Medical Wins Category I CPT Code for Subfascial Tibial Neuromodulation
2026-10-02 · Policy
Neurable One Brings Brain-Computer Interface Technology to Consumer Wireless Headphones
2026-10-01 · Product
Company details
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages →